Join to access to all OVN content. Join for Free

Results for 'Ken Schlosser'

...
Partner Avatar Michael Pietrack
Leadership Lab: 5 Ways Biopharma Execs Can Restore Trust, Retain Talent After Layoffs

Jun 25th • 4 mins read

...
Partner Avatar Michael Pietrack
Hiring Managers: What Should You Do During a Hiring Freeze?

Jan 26th • 5 mins read

...
Partner Avatar Tom Caravela
Mastering the First Impression

Jan 29th • 2 mins read

...
Partner Avatar Tom Caravela
Promotability: How to Land Your Next Promotion

May 5th • 10 mins read

...
Partner Avatar Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022

Dec 21st • 10 mins read

...
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep
Accelerated drug approvals in oncology: Pros and cons

Sep 14th • 4 mins read

...
OVN Avatar Fei Liang, Sheng Zhang, Qin Wang, Wenfeng Li
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

Aug 31st • 16 mins read

...
OVN Avatar Muneera Al Hussain
Comment on: Oncology research in Saudi Arabia over a 10-year period. A synopsis

Jun 24th • 3 mins read

...
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Jan 20th • 20 mins read

...
Partner Avatar Envision Pharma Group
Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

May 9th • 5 mins read

...
Partner Avatar Envision Pharma Group
Medical affairs: The power behind redefining commercialization

Aug 2nd • 3 mins read

...
OVN Avatar Kristina Jenei, BSN, MS, Daniel E. Meyers, MD, MS, Vinay Prasad, MD, MPH
The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years

Aug 26th • 2 mins read

...
OVN Avatar Cheryl Ho, MD, Howard J. Lim, MD, Dean A. Regier, PhD
Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program

Jun 5th • 6 mins read

...
OVN Avatar Emerson Y. Chen, MD, Vikram Raghunathan, MD, Vinay Prasad, MD, MPH
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate

May 28th • 5 mins read

...
OVN Avatar Jiaxi Zhou, Jonathon Vallejo, Paul Kluetz, Richard Pazdur, Tamy Kim, Patricia Keegan, Ann Farrell, Julia A Beaver, Rajeshwari Sridhara
Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016

Aug 4th • 15 mins read

Related Topics

Loading...